141 related articles for article (PubMed ID: 32798400)
21. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
22. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
23. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].
Lu GQ; Zhou XH; Chen H; Tan JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):733-7. PubMed ID: 27342500
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
Song Y; Zhou H; Zhang H; Liu W; Shuang Y; Zhou K; Lv F; Xu H; Zhou J; Li W; Wang H; Zhang H; Huang H; Zhang Q; Xu W; Ge Z; Xiang Y; Wang S; Gao D; Yang S; Lin J; Wang L; Zou L; Zheng M; Liu J; Shao Z; Pang Y; Xia R; Chen Z; Hou M; Yao H; Feng R; Cai Z; Zhang M; Ran W; Liu L; Zeng S; Yang W; Liu P; Liang A; Zuo X; Zou Q; Ma J; Sang W; Guo Y; Zhang W; Cao Y; Li Y; Feng J; Du X; Zhang X; Zhao H; Zhou H; Yu J; Sun X; Zhu J; Qiu L
Adv Ther; 2021 Apr; 38(4):1889-1903. PubMed ID: 33751401
[TBL] [Abstract][Full Text] [Related]
26. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
27. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.
Zhou D; Xie WZ; Hu KY; Huang WJ; Wei GQ; He JS; Shi JM; Luo Y; Li L; Zhu JJ; Zhang J; Lin MF; Ye XJ; Cai Z; Huang H
Asian Pac J Cancer Prev; 2013; 14(2):929-34. PubMed ID: 23621263
[TBL] [Abstract][Full Text] [Related]
28. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
29. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S
Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
31. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
32. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
33. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
34. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
[TBL] [Abstract][Full Text] [Related]
35. [Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma].
Maruyama D; Ohmachi K
Rinsho Ketsueki; 2021; 62(6):641-648. PubMed ID: 34219092
[TBL] [Abstract][Full Text] [Related]
36. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
37. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.
Shin DY; Byun BH; Kim KM; Kang JH; Lim I; Kim BI; Lee SS; Choi CW; Kang HJ; Lim SM
Cancer Chemother Pharmacol; 2016 Oct; 78(4):825-31. PubMed ID: 27577259
[TBL] [Abstract][Full Text] [Related]
39. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]